Weight loss drugs such as Ozempic (semaglutide) and Mounjaro (tirzepatide) have gained popularity for their effectiveness in helping individuals lose weight. However, not all users achieve the same results, with some struggling to lose even 5% of their body weight. A groundbreaking study published in the journal Nature reveals that genetic factors may play a crucial role in these differing outcomes. Researchers from 23andMe conducted a genome-wide association study (GWAS) on nearly 28,000 patients using these medications, identifying specific gene variants associated with weight loss success and side effects like nausea. Notably, the GLP1R gene variant rs10305420 was linked to a loss of approximately 0.76 kg (1.6 lbs) more per allele in carriers compared to non-carriers. The findings suggest that genetics could guide personalized obesity treatments, moving away from trial-and-error approaches. Experts recommend genetic testing to tailor treatment plans, potentially enhancing effectiveness and reducing dropout rates due to side effects. This approach could be particularly transformative in countries like India, where obesity affects over 135 million adults.